98. Eosinophilic gastrointestinal disease Clinical trials / Disease details

Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01040598 (ClinicalTrials.gov)	June 2009	27/12/2009	Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model	Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model	Eosinophilic Esophagitis	Biological: Omalizumab	O & O Alpan LLC	Genentech, Inc.	Completed	12 Years	76 Years	Both	19	Phase 1	United States
2	NCT00123630 (ClinicalTrials.gov)	November 2005	21/7/2005	A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab	A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab	Esophagitis	Drug: omalizumab;Drug: Placebo	University of Utah	Novartis Pharmaceuticals	Completed	12 Years	60 Years	All	30	Phase 2	United States
3	NCT00084097 (ClinicalTrials.gov)	June 2, 2004	5/6/2004	Omalizumab to Treat Eosinophilic Gastroenteritis	Pilot Study of Omalizumab in Eosinophilic Gastroenteritis	Gastroenteritis	Drug: Omalizumab	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	12 Years	76 Years	All	30	Phase 2	United States